Expert Ratings for Editas Medicine
Portfolio Pulse from Benzinga Insights
Editas Medicine (NASDAQ:EDIT) has received various analyst ratings in the last quarter, with 2 bullish, 2 somewhat bullish, and 1 indifferent. The average price target is $15.2, compared to its current price of $7.8092, implying an upside. This average has decreased by 1.94% from the previous average price target of $15.50.
September 29, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Editas Medicine has received mixed analyst ratings, with an average price target of $15.2, implying an upside from its current price.
The mixed analyst ratings indicate uncertainty about the company's performance. However, the average price target, which is almost double the current price, suggests that analysts see potential for growth. This could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100